文献速递瓣膜病与结构性心脏病

低外科风险患者经导管主动脉瓣置换术后2年结局

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

PARTNER 3试验随机分配1000例低外科风险的重度主动脉瓣狭窄患者,比较经股动脉TAVR(SAPIEN 3瓣膜)与外科手术。2年时TAVR组主要终点(死亡、卒中或再住院)显著低于手术组(11.5% vs 17.4%),但1年时死亡和卒中方面的优势在2年时不再显著,且TAVR组瓣膜血栓形成增加。

要点

  • TAVR组2年主要终点显著低于手术组(11.5% vs 17.4%,HR 0.63,95%CI 0.45-0.88,p=0.007)。
  • 2年时死亡和卒中差异不再显著(死亡2.4% vs 3.2%,p=0.47;卒中2.4% vs 3.6%,p=0.28)。
  • TAVR组2年瓣膜血栓形成高于手术组(2.6% vs 0.7%,p=0.02)。

核心结论

  • 2年时TAVR组主要终点仍显著低于手术组,但1年时死亡和卒中方面的优势在2年时减弱,且TAVR组瓣膜血栓形成增加。

研究设计与样本

  • PARTNER 3试验随机分配1000例低外科风险的重度主动脉瓣狭窄患者(1:1)至经股动脉TAVR(SAPIEN 3瓣膜)或外科手术,平均STS评分1.9%,平均年龄73岁。
  • 本分析为as-treated分析,评估2年主要终点及多个次要终点(临床、超声心动图和生活质量指标)。

主要发现

  • 2年主要终点随访率96.5%,TAVR组主要终点发生率11.5%,手术组17.4%(HR 0.63,95%CI 0.45-0.88,p=0.007)。
  • 2年死亡:TAVR组2.4% vs 手术组3.2%(p=0.47);卒中:TAVR组2.4% vs 手术组3.6%(p=0.28)。
  • 2年瓣膜血栓形成:TAVR组2.6%(13例) vs 手术组0.7%(3例)(p=0.02)。
  • 疾病特异性健康状况在TAVR组至2年时仍优于手术组。
  • 2年时超声心动图表现(包括血流动力学瓣膜退化和生物瓣膜衰竭)在TAVR和手术组间相似。

临床怎么用

  • 对于低外科风险的重度主动脉瓣狭窄患者,TAVR在2年主要终点上仍优于手术,但需关注瓣膜血栓形成风险增加。
  • TAVR后死亡和卒中方面的早期优势在2年时减弱,临床决策应综合长期获益与血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year. OBJECTIVES: This study determined both clinical and echocardiographic outcomes between 1 and 2 years in the PARTNER 3 trial. METHODS: This study randomly assigned 1,000 patients (1:1) to transfemoral TAVR with the SAPIEN 3 valve versus surgery (mean Society of Thoracic Surgeons score: 1.9%; mean age: 73 years) with clinical and echocardiography follow-up at 30 days and at 1 and 2 years. This study assessed 2-year rates of the primary endpoint and several secondary endpoints (clinical, echocardiography, and quality-of-life measures) in this as-treated analysis. RESULTS: Primary endpoint follow-up at 2 years was available in 96.5% of patients. The 2-year primary endpoint was significantly reduced after TAVR versus surgery (11.5% vs. 17.4%; hazard ratio: 0.63; 95% confidence interval: 0.45 to 0.88; p = 0.007). Differences in death and stroke favoring TAVR at 1 year were not statistically significant at 2 years (death: TAVR 2.4% vs. surgery 3.2%; p = 0.47; stroke: TAVR 2.4% vs. surgery 3.6%; p = 0.28). Valve thrombosis at 2 years was increased after TAVR (2.6%; 13 events) compared with surgery (0.7%; 3 events; p = 0.02). Disease-specific health status continued to be better after TAVR versus surgery through 2 years. Echocardiographic findings, including hemodynamic valve deterioration and bioprosthetic valve failure, were similar for TAVR and surgery at 2 years. CONCLUSIONS: At 2 years, the primary endpoint remained significantly lower with TAVR versus surgery, but initial differences in death and stroke favoring TAVR were diminished and patients who underwent TAVR had increased valve thrombosis. (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [PARTNER 3]; NCT02675114).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. J Am Coll Cardiol. 2021. PMID: 33663731. doi:10.1016/j.jacc.2020.12.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。